Sartorius (OTCMKTS:SARTF) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Sartorius (OTCMKTS:SARTF) from a buy rating to a hold rating in a research note released on Thursday morning, Zacks.com reports.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Separately, DZ Bank reiterated a sell rating on shares of Sartorius in a research note on Friday, July 19th.

Shares of SARTF opened at $164.10 on Thursday. Sartorius has a 52-week low of $109.50 and a 52-week high of $192.10. The business’s fifty day moving average is $181.39 and its 200-day moving average is $169.04. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.85 and a current ratio of 1.53. The firm has a market cap of $5.61 billion, a price-to-earnings ratio of 54.34 and a beta of -0.06.

Sartorius (OTCMKTS:SARTF) last issued its quarterly earnings results on Friday, July 19th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.80 by $0.07. Sartorius had a return on equity of 20.23% and a net margin of 11.10%. The company had revenue of $515.83 million for the quarter, compared to analyst estimates of $482.51 million. As a group, research analysts forecast that Sartorius will post 3.53 EPS for the current fiscal year.

About Sartorius

There is no company description available for Sartorius AG.

Recommended Story: What Factors Can Affect Return on Equity?

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.